The previous studies indicated that COVID19 patients have a high prevalence of liver injury and the degree of the injury is associated with the severity of the disease (Abdulla et al., 2020; Ahmed et al., 2020; Shokri Afra et al., 2020; Ye et al., 2021), suggesting that disturbed levels of liver biomarkers, such as AST, ALT, bilirubin and albumin, could serve as prognostic tools in assessing the COVID19. The gene discussed is ALB; the disease is COVID-19.